Azenta, Inc. (AZTA): Results of Operations and Financial Condition
Azenta, Inc. (AZTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 azta-2026q326erxexx991.htm EX-99.1 Document Exhibit 99.1 Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026. BURLINGTON, Mass., August 4, 2026 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended
How this was made
The 30-second read
Why it matters
Continuing-operations revenue rose to $161 million with organic growth, while GAAP EPS remained negative. Management also revised full-year revenue and organic growth expectations and provided an Adjusted EBITDA range, which are key inputs for valuation and near-term positioning.
Market read
Traders can update models using the new Q3 datapoints and the revised FY2026 continuing-operations guidance, especially organic revenue direction and Adjusted EBITDA expectations.
What to watch
The B Medical Systems segment is treated as discontinued operations, so traders should focus on continuing-operations trends and the drivers of gross margin decline from fixed-cost absorption and quality remediation.
Background
Azenta filed an 8-K with Q3 FY2026 results (ended June 30, 2026) and guidance updates for continuing operations; B Medical Systems is reported as discontinued operations after a sale closed July 1, 2026.
Ticker impact
Azenta reported Q3 FY2026 results and updated FY2026 guidance for continuing operations, including organic revenue and Adjusted EBITDA ranges.
Likely modest volatility around the open as traders weigh revenue growth versus continued GAAP EPS weakness and the updated organic growth outlook.
Revenue grew in Q3 and Adjusted EBITDA improved, but GAAP EPS remains negative and guidance shifts (organic flat to up 1% vs prior down 2% to up 1%). The market may focus on whether the turnaround is sustainable and whether Multiomics stabilization holds.
Market effects
Signals demand and margin pressure dynamics in lab/biotech tools and services, especially in recurring revenue and Multiomics performance.
No explicit regional shock; commentary highlights North America Multiomics modest improvement.
Foreign exchange and acquisition-related organic adjustments are discussed, but no global regulatory or supply-chain event is disclosed.
Counterpoint
Despite organic growth, GAAP operating loss and negative free cash flow in the quarter suggest the turnaround may still be fragile, and guidance could be conservative.
Key entities
- companyAzenta, Inc.
Nasdaq-listed life sciences tools/services company reporting Q3 FY2026 results and updated FY2026 guidance.
- business_unitB Medical Systems
Reported as discontinued operations following a sale agreement closed July 1, 2026.
- business_unitUK Biocentre Limited
Acquisition referenced in organic revenue adjustments affecting reported versus organic growth comparisons.
